Menu Search
Equities

D.Western Therapeutics Institute Inc

6DW:FRA

D.Western Therapeutics Institute Inc

Actions
  • Price (EUR)0.366
  • Today's Change0.002 / 0.55%
  • Shares traded--
  • 1 Year change-65.14%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year D.Western Therapeutics Institute Inc's revenues fell -4.40%from 448.10m to 428.36m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 89.07% reduction in net income from a loss of 429.69m to a larger loss of 812.41m.
Gross margin91.27%
Net profit margin-235.62%
Operating margin-233.50%
Return on assets-44.77%
Return on equity-81.33%
Return on investment-47.81%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at D.Western Therapeutics Institute Inc fell by 467.40m. Cash Flow from Financing totalled 134.47m or 31.39% of revenues. In addition the company used 586.82m for operations while cash used for investing totalled 15.25m.
Cash flow per share-32.44
Price/Cash flow per share--
Book value per share25.80
Tangible book value per share23.83
More ▼

Balance sheet in JPYView more

D.Western Therapeutics Institute Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.66% of the market capitalization can be attributed to its 1.87bn and debt could be paid in full if management chose.
Current ratio19.32
Quick ratio18.24
Total debt/total equity1.30
Total debt/total capital0.5644
More ▼

Growth rates in JPY

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-82.30
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.